Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

I was factoring that in. Going from no partner/phase3 start to market sales in 30 months is extremely aggressive even with fast track.

As more B research results have rolled in expanding B's virucidal scope,
why would Leo pivot back to B for OM and get a payer analysis done if there is no interest?

For now I think further preclinical antiviral results are not worth much. We had great COVID preclinical results and we ended up with a trial failure. The answer to "Can we dose enough Brilacidin to have high efficacy in viral indications without hitting the side effect ceiling?" is still unanswered.

Payer analysis does not cost much to do relative to clinical work. Yes, perhaps a partner is waiting on it to finalize a term sheet. Or, perhaps it's time for IPIX to do a capital raise and Leo is attempting to generate interest. Maybe Leo wants to authorize more shares and needs some new info on the table to propose a vote? Or perhaps it's one of a dozen different reasons.

I like what I saw in the payer analysis but the fact of the matter is this company and its leadership has screwed up almost every indication we have had (either with a trial or a bad deal). Skepticism is the default approach for me and the broader market as can be seen from the stock price.

My last buy was $0.08 on the day of the COVID results. I thought we were undervalued then and more so now IF this company is not turning into Leo's personal retirement plan.

We will see. My options now are book a near total loss or hope. I don't need the loss right now, so I'm hoping Leo gets it together in ways he never has before.

Eagerly awaiting the announcement of a B-OM deal:

$20M upfront + $90M milestones + 9% royalty for the development of Brilacidin-OM.

I hope you are right.